Search
Displaying 1–10 of 37 news results
-
The Foundation in the News
On World Sight Day 2022, Retina International is presenting data from a report on its study into the Socio-economic Impact of late-stage age-related macular degeneration (AMD) in Bulgaria, Germany, and USA.
-
RD Fund Participates in a €75 Million Series B for SparingVision
The Foundation in the NewsProceeds to fund first, in-human trials of breakthrough gene-agnostic therapy products and advance CRISPR-based genome editing portfolio.
-
Progress toward a stem cell–based therapy for blindness
The Foundation in the NewsA multi-institutional effort led by researchers at the School of Veterinary Medicine is taking steps to develop an effective technique to regenerate photoreceptors cells and restore sight in people with vision disorders.
-
RD Fund Announces New Chair, and Expansion of Board of Directors
The Foundation in the NewsRD Fund Board member and seasoned ophthalmology leader Adrienne Graves, PhD, appointed chair. Ophthalmology luminaries Jean Bennett, MD, PhD, Catherine Bowes Rickman, PhD, and José-Alain Sahel, MD, to join the board.
-
The Foundation in the News
Funds to support advancement of two clinical trials through proof of concept: NPI-001 for retinitis pigmentosa in Usher syndrome and NPI-002 to slow cataract progression.
-
Opus Genetics Appoints Jennifer Hunt Chief Development Officer
The Foundation in the NewsBiopharma clinical development veteran to propel Opus’ AAV-based gene therapies for inherited retinal diseases toward patients.
-
Clearside Biomedical Appoints Benjamin R. Yerxa, Ph.D. to its Board of Directors
The Foundation in the NewsIndustry Veteran Brings Broad Ophthalmology Research & Development Expertise.
-
RD Fund Announces Series B Financing Behind SalioGen Therapeutics
The Foundation in the NewsInvestment in new portfolio company furthering genetic medicine approaches for individuals affected by retinal degenerative diseases.
-
The Foundation in the News
Series B new investors included Fidelity Management & Research Company LLC, funds and accounts advised by T. Rowe Price Associates, Inc., D1 Capital Partners, SymBiosis, the Cystic Fibrosis Foundation, and the RD Fund (the venture arm of Foundation Fighting Blindness).
-
The Foundation in the News
Dr. Thomas Chalberg has been recognized by the Foundation Fighting Blindness for his pioneering contributions to research and development.
